and its collection sets were used in the landmark Cord Blood Transplantation
(COBLT) study which defines the standards on the use of stem cells from umbilical cord blood.
It is expected that this rapid engraftment will reduce the risk of opportunistic infections, will lower the morbidity associated with cord blood transplantation
and shorten hospitalization.
Expensive cord blood transplantation
procedures, costing from $200-300K each
They describe stem cells found in amniotic fluid, the clinical practice of cord blood transplantation
, hematopoietic stem cell development in the placenta and transplantation, uses for preventing and treating complications after transplantation, cord tissue/Wharton's jelly-derived stem cells, immunogeniocity and immunomodulatory effects, uses in treating and preventing graft-versus-host disease in hematopoietic transplantation, the amnion and regenerative medicine applications, the role of stem cells in regenerative medicine, the amniotic membrane, and fetal stem cells in maternal circulation.
Cord Blood Transplantation
Trends: Age of Recipient, Disease Classes Addressed
Demand for cord blood could increase or decrease depending on a number of variables, such as whether new research identifies ways to increase the benefits of cord blood or conversely, the development of alternative treatments to cord blood transplantation
Allogeneic cord blood transplantation
(CBT), especially from unrelated donors, has become an extensively used treatment for patients with both malignant and nonmalignant disorders (1).
Advances in cord blood transplantation
indicate that the trend will continue as reliance on cord blood accelerates," Jeff Chell, MD, NMDP CEO said in NMDP's Quarterly Review, which reported the increase.
Alternative sources of stem cells, including MUD and umbilical cord blood transplantation
, have widened the availability of donors throughout the world.
With its partners, StemCyte is actively involved in the development of new umbilical cord blood-based cell therapies and has the largest clinical study for using unrelated cord blood transplantation
for thalassemia, one of the most common genetic diseases in the world.
Another innovation in which the BMT program at Minnesota has been a driving force is that of umbilical cord blood transplantation
Other topics include angiogenesis inhibitors, molecular approaches in pediatric oncology, enzyme replacement for lysosomal diseases, umbilical cord blood transplantation
and banking, and implications of HIPAA for clinical research.